---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Cost-effectiveness evidence"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Cost-effectiveness evidence. Topics: Summary: published economic evaluations, HTA status, and commercial forecasts; Cost-effectiveness of emerging APOL1-targeted therapies; Cost analysis of APOL1 genotyping of potential living kidney donors; Revenue forecast for inaxaplin in the United States; 1 further topic. 5 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics/cost-effectiveness"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Cost-effectiveness evidence

<a id="heading-4.1"></a>

## 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

### Summary: published economic evaluations, HTA status, and commercial forecasts

No published cost-effectiveness analysis, budget impact model, or health technology assessment of inaxaplin or of any other APOL1-targeted therapy was identified, and no ICER review was identified. A 2025 narrative review states that the cost-effectiveness of emerging APOL1-targeted therapies “remains uncertain”. The only APOL1-related economic analysis identified is a “crude cost analysis” of donor genotyping at one center, in which 1 of 26 potential African American living donors had a high-risk genotype. A GlobalData forecast published in 2024 projects U.S. inaxaplin revenue of $138 million in 2034. Guggenheim Securities analysts assigned a 65% probability of success in primary AMKD and 45% in the type 2 diabetes population; Vertex investor relations stated that AMPLITUDE could address about 150,000 people in the U.S. and Europe ; Fierce Biotech reported that an FDA label covering the two AMPLIFIED cohorts would add about 100,000.

Source: [Adebayo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12822060/); [Gudsoorkar et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31940609/); [GlobalData via Pharmaceutical Technology (2024)](https://www.pharmaceutical-technology.com/data-insights/inaxaplin-vertex-pharmaceuticals-net-present-value-3); [Fierce Biotech (2026)](https://www.fiercebiotech.com/biotech/vertexs-midstage-data-amplify-kidney-disease-market-opportunity)

<a id="topic-4.1-2"></a>

### Published cost-effectiveness analyses, budget impact models, and HTA reviews of inaxaplin

No evidence found.

<a id="topic-4.1-3"></a>

### Cost-effectiveness of emerging APOL1-targeted therapies

> “At present, the cost-effectiveness of the aforementioned emerging therapeutic strategies remains uncertain.”
> “If similar pricing were applied to therapies for APOL1-mediated kidney disease, such intervention would be unaffordable in sub-Saharan Africa, the region bearing the highest disease burden.”

Source: [Adebayo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12822060/)

<a id="topic-4.1-4"></a>

### Cost analysis of APOL1 genotyping of potential living kidney donors

> “A crude cost analysis utilizing our sample suggested probable cost-effectiveness of APOL1 genotyping as it can prevent earlier onset of chronic kidney disease in AA donors.”

Source: [Gudsoorkar et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31940609/)

<a id="topic-4.1-5"></a>

### Revenue forecast for inaxaplin in the United States

> “The revenue for Inaxaplin is expected to reach an annual total of $138 mn by 2034 in the US”

Source: [GlobalData via Pharmaceutical Technology (2024)](https://www.pharmaceutical-technology.com/data-insights/inaxaplin-vertex-pharmaceuticals-net-present-value-3)

<a id="topic-4.1-6"></a>

### Analyst probability of success and company estimates of the addressable population

> “Amplitude could unlock a population with about 150,000 patients in the U.S. and Europe”
> “An FDA label covering the two arms in Amplified would add about 100,000 patients to the target population.”
> “In an Aug. 3 note to investors, Guggenheim Securities analysts put the probability of success in primary AMKD at 65%.”
> “The analysts see the Type 2 diabetes population as a longer shot, ascribing a 45% chance of success to the indication.”

Source: [Fierce Biotech (2026)](https://www.fiercebiotech.com/biotech/vertexs-midstage-data-amplify-kidney-disease-market-opportunity)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
